Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to -$2.7 million.

  • Marker Therapeutics' Free Cash Flow fell 32846.58% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.8 million, marking a year-over-year decrease of 7279.89%. This contributed to the annual value of -$10.9 million for FY2024, which is 3363.53% up from last year.
  • Latest data reveals that Marker Therapeutics reported Free Cash Flow of -$2.7 million as of Q3 2025, which was down 32846.58% from -$1.9 million recorded in Q2 2025.
  • Marker Therapeutics' Free Cash Flow's 5-year high stood at $1.5 million during Q2 2022, with a 5-year trough of -$14.6 million in Q1 2022.
  • For the 5-year period, Marker Therapeutics' Free Cash Flow averaged around -$5.0 million, with its median value being -$5.5 million (2025).
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 56496.58% in 2023, then skyrocketed by 20621.22% in 2024.
  • Marker Therapeutics' Free Cash Flow (Quarter) stood at -$6.9 million in 2021, then grew by 9.61% to -$6.3 million in 2022, then surged by 62.3% to -$2.4 million in 2023, then crashed by 98.65% to -$4.7 million in 2024, then soared by 41.83% to -$2.7 million in 2025.
  • Its Free Cash Flow was -$2.7 million in Q3 2025, compared to -$1.9 million in Q2 2025 and -$5.5 million in Q1 2025.